Related Experiment Video

Updated: Feb 6, 2026

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
05:06

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Published on: October 24, 2015

12.9K

Amentoflavone Inhibits Hepatocellular Carcinoma Progression Through Blockage of ERK/NF-ĸB Activation

Kun-Ching Lee1,2, Wei-Ting Chen1,3, Yu-Chang Liu1,2

  • 1Department of Medical Imaging and Radiological Sciences, Central-Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.

In Vivo (Athens, Greece)
|August 29, 2018
PubMed
Abstract

Insights

Amentoflavone effectively inhibited hepatocellular carcinoma (HCC) growth in mice by suppressing extracellular signal-regulated kinase (ERK)/nuclear factor-kappaB (NF-ĸB) signaling, without causing toxicity.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Hepatocellular carcinoma (HCC) is a major global health concern.
  • Identifying novel therapeutic agents for HCC is critical.
  • Amentoflavone is a natural compound with potential anti-cancer properties.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of amentoflavone in HCC.
  • To elucidate the mechanism of action of amentoflavone in HCC.
  • To confirm amentoflavone's effects in an in vivo HCC model.

Main Methods:

  • Mice bearing SK-Hep1/luc2 tumors were treated with amentoflavone (100 mg/kg/day) or vehicle for 14 days.
  • Tumor growth was monitored using bioluminescence imaging and computed tomography.
  • Extracellular signal-regulated kinase (ERK)/nuclear factor-kappaB (NF-ĸB) signaling pathways were assessed via immunohistochemistry.

Main Results:

  • Amentoflavone significantly suppressed tumor growth compared to the vehicle group.
  • Amentoflavone inhibited ERK/NF-ĸB activation and expression of tumor progression markers.
  • No significant toxicity was observed in body weight or liver morphology.

Conclusions:

  • Amentoflavone demonstrates therapeutic efficacy against HCC in vivo.
  • Amentoflavone inhibits HCC progression by suppressing the ERK/NF-ĸB signaling pathway.
  • Amentoflavone represents a potential therapeutic candidate for hepatocellular carcinoma.
Keywords:
Amentoflavonebioluminescence imagingextracellular signal-regulated kinasehepatocellular carcinomanuclear factor-kappaB

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.2K
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

37.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
8.7K